Previously the company announced 26-week data that tracked a sub-population living with the muscle-specific kinase autoantibody-positive (MuSK+) variant of the disease. In those results ...

The new 52-week data from the study only applies to the AChR+ cohort, as the smaller MuSK+ group did not receive treatment beyond 26 weeks. After a year, 72.3% of the Uplizna group had three-point ...

(RTTNews) - Amgen Inc. (AMGN) Thursday announced positive data from the Phase 3 MINT study of Uplizna in adults with generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune ...

The Phase 3 MINT trial, which was a randomized-control trial, evaluated Uplinza in muscle-specific kinase autoantibody-positive and AChR+ gMG patients, with the MuSK+ group followed for 26 weeks ...

including 190 patients who were AChR+ and 48 patients who were muscle-specific kinase autoantibody-positive (MuSK+). Patients were eligible for the study if they had Myasthenia Gravis Foundation ...

The MINT trial, a randomized-control study, followed AChR+ gMG patients for a year and muscle-specific kinase autoantibody-positive (MuSK+) gMG patients for 26 weeks. Results indicated a ...

The MINT trial, a randomized-control study, followed AChR+ gMG patients for a year and muscle-specific kinase autoantibody-positive (MuSK+) gMG patients for 26 weeks. Results indicated a significant ...

The trial enrolled 238 adults from 104 international sites, comprising 190 patients in the AChR+ group and 48 patients in the MuSK+ group. Credit: shutterstock / CGN089. Amgen’s Uplizna ...